Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

Objective To assess the effectiveness, safety, and tolerability of erenumab in a real‐life migraine population, while trying to identify responsiveness predictors. Background Erenumab is a fully human Ig‐2 monoclonal antibody blocking the calcitonin gene‐related peptide receptor, indicated for migra...

Full description

Saved in:
Bibliographic Details
Published in:Headache 2021-02, Vol.61 (2), p.363-372
Main Authors: Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Cevoli, Sabina, Colombo, Bruno, Filippi, Massimo, Frediani, Fabio, Bono, Francesco, Grazzi, Licia, Salerno, Antonio, Mercuri, Bruno, Carnevale, Antonio, Altamura, Claudia, Vernieri, Fabrizio
Format: Article
Language:English
Subjects:
Adult
Analgesics
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - pharmacology
Calcitonin
Calcitonin Gene-Related Peptide Receptor Antagonists - administration & dosage
Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology
Calcitonin gene‐related peptide
Clinical trials
Cost of Illness
Disease prevention
Dopamine receptors
Effectiveness
Erenumab
Female
Headache
Humans
Immunoglobulins
Impact tests
Italy
Localization
Male
Middle Aged
Migraine
Migraine Disorders - prevention & control
Monoclonal antibodies
Outcome Assessment, Health Care
Pain
Pain Measurement
Patients
Prevention
Prospective Studies
Real‐life
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!